How we work

Zambon S.p.A. is the group’s company responsible for the pharmaceutical business

With a recognized international reputation as a healthcare company and 2,800 employees in 19 countries in Europe, America and Asia., the Zambon group is a pharmaceutical and fine chemicals family enterprise on the market for over 110 years. Respiratory, pain and woman care are the three therapeutic areas of excellence in addition to orphan drugs such as cystic fibrosis, and Parkinson's Disease with the recent launch of a new chemical entity, the first on the market in a decade. Zambon products are marketed in 84 countries and in 2016 revenues amounted to 600 million euros.

In 2016 the different therapeutic areas have achieved the following results:

  • CSN 3%
  • Orphan drug 6%
  • Respiratory  44%
  • Women care  19%
  • Pain management  11%
  • Others 17%

 

 

In 2016, the Industrial Business Operation reached a total production of 163 million packs,  an increase of  8% on the previous year with production facilities in Italy, Switzerland, France, Brazil, China. In the past three years, the company has embraced the Industry 4.0 approach, the new frontier of  manufacturing production characterized by fully automated and interconnected industrial processes, investing over 10 million euros for the adoption of new technological platforms in Italy and abroad.

Today Zambon is an increasingly global reality in 84 countries of the 5 continents.

The Industrial Business overview:

  • Europa 27%
  • Nord America 13%
  • Sud America 15%
  • Asia 33%
  • Africa 12%